352 related articles for article (PubMed ID: 29167667)
21. Effects of BTK signalling in pathogenic microorganism infections.
Ye B; Zhou C; Guo H; Zheng M
J Cell Mol Med; 2019 Oct; 23(10):6522-6529. PubMed ID: 31397086
[TBL] [Abstract][Full Text] [Related]
22. The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation.
Murthy P; Durco F; Miller-Ocuin JL; Takedai T; Shankar S; Liang X; Liu X; Cui X; Sachdev U; Rath D; Lotze MT; Zeh HJ; Gawaz M; Weber AN; Vogel S
Biochem Biophys Res Commun; 2017 Jan; 483(1):230-236. PubMed ID: 28034752
[TBL] [Abstract][Full Text] [Related]
23. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
[TBL] [Abstract][Full Text] [Related]
24. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
Xia B; Qu F; Yuan T; Zhang Y
Oncol Lett; 2015 Dec; 10(6):3339-3344. PubMed ID: 26788133
[TBL] [Abstract][Full Text] [Related]
25. Bruton's tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses in macrophages.
Liljeroos M; Vuolteenaho R; Morath S; Hartung T; Hallman M; Ojaniemi M
Cell Signal; 2007 Mar; 19(3):625-33. PubMed ID: 17020802
[TBL] [Abstract][Full Text] [Related]
26. Specific binding of the WASP N-terminal domain to Btk is critical for TLR2 signaling in macrophages.
Sakuma C; Sato M; Takenouchi T; Kitani H
Mol Immunol; 2015 Feb; 63(2):328-36. PubMed ID: 25213142
[TBL] [Abstract][Full Text] [Related]
27. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.
Mohamed AJ; Yu L; Bäckesjö CM; Vargas L; Faryal R; Aints A; Christensson B; Berglöf A; Vihinen M; Nore BF; Smith CI
Immunol Rev; 2009 Mar; 228(1):58-73. PubMed ID: 19290921
[TBL] [Abstract][Full Text] [Related]
28. Production of monoclonal antibodies to Bruton's tyrosine kinase.
Stewart DM; Kurman CC; Nelson DL
Hybridoma; 1995 Jun; 14(3):243-6. PubMed ID: 7590786
[TBL] [Abstract][Full Text] [Related]
29. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region.
Maas A; Dingjan GM; Grosveld F; Hendriks RW
J Immunol; 1999 Jun; 162(11):6526-33. PubMed ID: 10352268
[TBL] [Abstract][Full Text] [Related]
30. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
Horwood NJ; Mahon T; McDaid JP; Campbell J; Mano H; Brennan FM; Webster D; Foxwell BM
J Exp Med; 2003 Jun; 197(12):1603-11. PubMed ID: 12810683
[TBL] [Abstract][Full Text] [Related]
31. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
García-Merino A
Cells; 2021 Sep; 10(10):. PubMed ID: 34685540
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families.
Guo S; Wahl MI; Witte ON
Int Immunol; 2006 Jan; 18(1):79-87. PubMed ID: 16291652
[TBL] [Abstract][Full Text] [Related]
33. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages.
de Weers M; Verschuren MC; Kraakman ME; Mensink RG; Schuurman RK; van Dongen JJ; Hendriks RW
Eur J Immunol; 1993 Dec; 23(12):3109-14. PubMed ID: 8258324
[TBL] [Abstract][Full Text] [Related]
34. Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells.
Zorn CN; Keck S; Hendriks RW; Leitges M; Freudenberg MA; Huber M
Cell Signal; 2009 Jan; 21(1):79-86. PubMed ID: 18848985
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.
Chalmers SA; Doerner J; Bosanac T; Khalil S; Smith D; Harcken C; Dimock J; Der E; Herlitz L; Webb D; Seccareccia E; Feng D; Fine JS; Ramanujam M; Klein E; Putterman C
Sci Rep; 2016 May; 6():26164. PubMed ID: 27192942
[TBL] [Abstract][Full Text] [Related]
36. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
[TBL] [Abstract][Full Text] [Related]
37. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
Smith CI; Baskin B; Humire-Greiff P; Zhou JN; Olsson PG; Maniar HS; Kjellén P; Lambris JD; Christensson B; Hammarström L
J Immunol; 1994 Jan; 152(2):557-65. PubMed ID: 8283037
[TBL] [Abstract][Full Text] [Related]
38. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
Arneson LC; Carroll KJ; Ruderman EM
Immunotargets Ther; 2021; 10():333-342. PubMed ID: 34485183
[TBL] [Abstract][Full Text] [Related]
39. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
Pérez de Diego R; López-Granados E; Pozo M; Rodríguez C; Sabina P; Ferreira A; Fontan G; García-Rodríguez MC; Alemany S
J Allergy Clin Immunol; 2006 Jun; 117(6):1462-9. PubMed ID: 16751014
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
Lindvall JM; Blomberg KE; Väliaho J; Vargas L; Heinonen JE; Berglöf A; Mohamed AJ; Nore BF; Vihinen M; Smith CI
Immunol Rev; 2005 Feb; 203():200-15. PubMed ID: 15661031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
